• Written by: James Carey, CA CTA
• 26/02/2026

How to Register a Healthcare Company in Australia [Foreign Company Guide 2026]

Australia's healthcare sector is valued at over $215 billion and is projected to reach $390 billion by 2034. For foreign healthcare, medtech, and pharmaceutical companies, Australia offers universal healthcare coverage through Medicare, a globally respected regulatory framework under the Therapeutic Goods Administration (TGA), generous R&D tax incentives for clinical trials, and a gateway to the broader Asia-Pacific region.

But entering the Australian healthcare market is not straightforward. You need to understand TGA sponsor obligations, medical device classification, clinical trial pathways, privacy legislation governing health data, and workforce registration under AHPRA — all before you supply a single product or treat a single patient.

This guide covers everything a foreign healthcare company needs to know about establishing operations in Australia in 2026.

Table of Contents

• Why Australia for Healthcare Companies
• Choosing the Right Entity Structure
• The TGA Regulatory Framework
• ARTG: The Australian Register of Therapeutic Goods
• Medical Device Classification and Conformity Assessment
• Clinical Trials: CTN and CTA Pathways
• AHPRA: Employing Health Practitioners
• PBS Listing for Pharmaceuticals
• Privacy and Health Data Requirements
• Workforce Considerations
• Cost Breakdown
• Frequently Asked Questions

Why Australia for Healthcare Companies

A $215+ Billion Healthcare Economy

Australia's healthcare services market exceeded $215 billion in 2025, making it one of the largest healthcare economies in the Asia-Pacific. Growth is driven by an aging population, rising chronic disease prevalence, and digital health transformation, with the market projected to grow at approximately 6.7% annually through 2034.

Universal Healthcare and the PBS

Australia's Medicare system provides universal coverage for all citizens and permanent residents, creating stable government-funded demand for healthcare products. The Pharmaceutical Benefits Scheme (PBS) subsidises prescription medicines, meaning pharmaceutical companies that secure PBS listing gain access to a large, government-supported patient population.

Globally Recognised Regulatory Framework

The TGA is recognised internationally as a stringent regulatory authority. TGA approval carries weight with regulators across Asia-Pacific. The TGA also recognises approvals from comparable bodies including the FDA, EMA, Health Canada, and UK MHRA, which can streamline registration for products already approved in those jurisdictions.

Clinical Trial Advantages and R&D Tax Incentive

The Clinical Trial Notification (CTN) pathway allows trials to begin without formal TGA evaluation, with approval in as little as five weeks. Clinical trial data generated in Australia is accepted by the FDA, EMA, and other major regulators.

Australia's R&D Tax Incentive offers companies with turnover below $20 million a 43.5% refundable tax offset on eligible R&D expenditure. For foreign companies conducting clinical trials in Australia, the government effectively co-funds nearly half of eligible trial costs as a cash refund.

MedTech Innovation Ecosystem

Australia has a mature medtech ecosystem anchored by world-class research institutions including the Walter and Eliza Hall Institute, the Garvan Institute, and CSIRO. Melbourne, Sydney, and Brisbane are established hubs for medical device development, digital health, and biotechnology.

Choosing the Right Entity Structure

Entity structure matters more in healthcare than in most industries because of TGA sponsor requirements. The wrong structure can prevent you from holding ARTG entries or sponsoring clinical trials.

Pty Ltd — Essential for Healthcare Companies

An Australian proprietary limited company (Pty Ltd) is essential for foreign healthcare companies entering Australia:

• TGA sponsor eligibility. A TGA sponsor must be a body corporate incorporated in Australia, carrying on business in Australia. A Pty Ltd satisfies this. A foreign branch office cannot independently act as a TGA sponsor.
• ARTG entry holder. Only an Australian sponsor can hold entries on the ARTG. Your Pty Ltd subsidiary becomes the legal entity responsible for all products in the register.
• IP protection. A Pty Ltd subsidiary can hold Australian IP — patents, pharmaceutical formulations, clinical data — creating a clean structure that simplifies R&D Tax Incentive claims.
• Limited liability. The foreign parent's liability is limited to the subsidiary's assets, which matters given healthcare product liability exposure.

Holding Company Structure

Many pharmaceutical and medtech companies establish a holding company structure with an Australian Pty Ltd operating subsidiary. Intellectual property stays with the foreign parent or a dedicated IP entity, while the Australian subsidiary handles TGA sponsorship and day-to-day operations.

Branch Office — Limited Use in Healthcare

A branch office (ARBN) cannot independently act as a TGA sponsor, exposes the parent to full liability, and complicates R&D Tax Incentive claims. It may suit companies providing only non-regulated services such as health IT consulting.

The TGA Regulatory Framework

The Therapeutic Goods Administration regulates prescription and over-the-counter medicines, medical devices, biologicals, and blood products in Australia.

TGA Sponsor Obligations

Under the Therapeutic Goods Act 1989, a sponsor is the entity legally responsible for importing, manufacturing, or supplying therapeutic goods. The sponsor must be an Australian resident or a body corporate incorporated in Australia with a representative residing in Australia.

Key obligations include regulatory compliance for manufacturing and labelling, maintaining ARTG entries, adverse event reporting within mandatory timeframes, coordinating product recalls, post-market surveillance, and ensuring manufacturing facilities meet Good Manufacturing Practice (GMP) standards.

Foreign companies can engage third-party TGA sponsors, but this means the third party holds your ARTG entries and controls your products in Australia — a risk most serious market entrants prefer to avoid by establishing their own entity.

GMP Certification

The TGA recognises GMP certificates from PIC/S member countries, the EU, and other recognised bodies. Your existing overseas manufacturing facilities may already meet TGA GMP requirements, verified through desk-based assessment or on-site audit.

ARTG: The Australian Register of Therapeutic Goods

No therapeutic good can be lawfully supplied in Australia unless entered on the ARTG. There are three entry categories:

• Listed (AUST L) — Lower-risk products, self-assessed by the sponsor, no pre-market TGA evaluation. Faster time to market.
• Registered (AUST R) — Higher-risk products including prescription medicines and most devices above Class I. Full TGA pre-market evaluation required. Timelines of 6 to 18+ months.
• Included (AUST I) — Assessed listed medicines requiring additional scrutiny. Pre-market assessment between listing and registration.

ARTG entries do not expire but require annual charges. The TGA publishes updated fee schedules each financial year.

Medical Device Classification and Conformity Assessment

Australia uses a risk-based classification system for medical devices:

Class I devices require only manufacturer self-declaration. Class IIa and above require conformity assessment certification. Class III and AIMD devices require full conformity assessment for both manufacturing and design.

IVDs and Conformity Assessment Pathways

In-vitro diagnostic devices (IVDs) have a separate four-class system based on public health risk from incorrect results, ranging from Class 1 (low risk, e.g., general laboratory reagents) to Class 4 (high risk, e.g., HIV screening tests).

The TGA offers two conformity assessment pathways: direct TGA assessment (required for AIMD and Class III) and comparable overseas assessment. If your device holds a CE mark from an EU Notified Body, the ARTG application is significantly streamlined — but you must still apply for ARTG inclusion. No mutual recognition arrangement grants automatic market access.

Clinical Trials: CTN and CTA Pathways

Australia offers two pathways for clinical trials involving unapproved therapeutic goods.

Clinical Trial Notification (CTN)

Used for approximately 90% of Australian trials. The sponsor provides documentation to a Human Research Ethics Committee (HREC), which reviews and approves the trial. The sponsor then notifies the TGA. No TGA evaluation of the product is required, and approval can take as little as 5 weeks.

Clinical Trial Approval (CTA)

Formerly known as CTX, this pathway involves formal TGA evaluation before the trial proceeds. The sponsor submits comprehensive clinical and pre-clinical data, and the TGA evaluates safety data before HREC approval is sought. CTA is appropriate for novel compounds with limited safety data or first-in-human studies.

AHPRA: Employing Health Practitioners

AHPRA regulates 16 health professions in Australia, including medical practitioners, nurses, pharmacists, dentists, psychologists, and physiotherapists. Any individual practising in these professions must hold current AHPRA registration.

Requirements for International Practitioners

Foreign healthcare companies hiring practitioners from overseas must ensure they obtain AHPRA registration. Requirements include qualification assessment against Australian standards, English language proficiency (IELTS, OET, or PTE Academic), international criminal history checks, and a Certificate of Good Standing from every jurisdiction where they have been registered.

Employer Obligations

Employers must verify AHPRA registration before employment begins, ensure practitioners maintain current registration, report notifiable conduct (mandatory reporting), and provide professional indemnity insurance.

PBS Listing for Pharmaceuticals

PBS listing means the Australian Government subsidises the cost of a medicine, dramatically increasing uptake. The process:

1. TGA registration — medicine must first be on the ARTG
2. PBAC submission — clinical evidence, cost-effectiveness analysis, and budget impact analysis to the Pharmaceutical Benefits Advisory Committee (meetings in March, July, November)
3. Price negotiation — with the Pharmaceutical Benefits Pricing Authority
4. Ministerial decision and listing

The process typically takes 12 to 24 months. Approximately 40% of major submissions are rejected at first attempt, so engaging health economics expertise early is critical.

Privacy and Health Data Requirements

Healthcare companies must comply with multiple layers of privacy legislation:

• Privacy Act 1988 — health information is classified as sensitive information requiring consent for collection, restricted use and disclosure, higher security standards, and individual access rights. Applies to all health service providers regardless of turnover.
• My Health Records Act 2012 — strict controls on access to the national digital health records system, audit logging, and penalties for unauthorised access.
• Healthcare Identifiers Act 2010 — governs 16-digit unique identifiers for individuals (IHI), practitioners (HPI-I), and organisations (HPI-O). Criminal and civil penalties for unauthorised use.
• State legislation — NSW, Victoria, and the ACT have additional health records legislation that may impose further requirements.

Workforce Considerations

Skilled Visa Pathways

Healthcare occupations appear prominently on Australia's skills shortage lists. Key visa options include Subclass 482 (Temporary Skill Shortage, up to 4 years), Subclass 494 (Skilled Employer Sponsored Regional), and Subclass 186 (Employer Nomination Scheme for permanent residency).

Modern Awards and Superannuation

Australia's Fair Work system includes Modern Awards setting minimum pay rates, overtime, and penalty rates for healthcare workers. Key awards cover health professionals, nurses, pharmaceutical workers, and medical practitioners. All employees are entitled to superannuation at 12% of ordinary time earnings.

Cost Breakdown

Entity and Establishment

TGA and Regulatory

TGA fees are updated annually. Check the TGA fees and charges page for current amounts.

Frequently Asked Questions

Can a foreign company act as a TGA sponsor without an Australian entity?

No. A TGA sponsor must be an Australian resident or a body corporate incorporated in Australia. Foreign companies must establish an Australian Pty Ltd or engage a third-party sponsor. Establishing your own entity gives you direct control over ARTG entries and regulatory obligations.

Does the TGA recognise FDA or CE mark approvals?

The TGA recognises comparable overseas approvals, which can streamline assessment, but recognition does not mean automatic approval. You must still apply for ARTG inclusion. For medical devices, CE mark certificates from EU Notified Bodies can be used through the comparable overseas assessment pathway.

How long does it take to register a medical device?

Class I devices can be included in the ARTG within 2 to 4 weeks. Class IIa/IIb devices using comparable overseas assessment take 3 to 6 months. Class III devices requiring TGA conformity assessment can take 6 to 18 months.

What is the difference between CTN and CTA?

CTN (Clinical Trial Notification) requires only HREC approval and TGA notification — no TGA product evaluation needed. CTA (Clinical Trial Approval, formerly CTX) requires formal TGA evaluation before HREC approval. CTN covers about 90% of Australian trials and suits products with established safety profiles.

Do I need a resident director for a healthcare company?

Yes. All Australian Pty Ltd companies must have at least one director who ordinarily resides in Australia. This is a Corporations Act requirement. If you do not have Australian-based management, you will need a resident director service.

Next Steps

Australia's healthcare market offers substantial opportunity for foreign healthcare, medtech, and pharmaceutical companies. The regulatory complexity is higher than in most sectors, but the large market, respected regulatory framework, and generous R&D incentives make it compelling.

Australian Business Register helps foreign healthcare companies with the establishment process — from company formation and resident director services to ABN and GST registration. We handle the corporate and compliance foundations so you can focus on regulatory and commercial strategy.

Request a quote for your healthcare company setup, or call us at +61 2 8599 9890 to discuss your requirements.